A Phase 3 interventional study of Acetazolamide and Furosemide in Heart Failure, sponsored by University Hospital, Montpellier. Not yet recruiting at 25 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by University Hospital, Montpellier · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.
Among the 14 studies testing acetazolamide in Heart Failure, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 13th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Johannes Grand · Sites in Denmark
Ages 18+
Universitas Diponegoro · Sites in Indonesia
Ages 18+
Lucrecia Maria Burgos
Ages 18+
Clinica Alemana de Santiago
Ages 18+
By country, each count listing its studies:
Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 366 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 14 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
19 studies in Heart Failure by University Hospital, Montpellier: 5 open now, 6 under way, 1 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 19 studies in Heart Failure by University Hospital, Montpellier, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 3, and was the 19th registered.
University Hospital, Montpellier’s Heart Failure studies by the year they started, since 2013.
3 of the studies testing acetazolamide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593612Lucrecia Maria BurgosTACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure | 2027-01-15 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT06273397Clinica Alemana de SantiagoAcetazolamide or Metolazone in Acute Heart Failure | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing acetazolamide in Heart Failure, from their registry updates:
Among University Hospital, Montpellier’s 19 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
Acute congestion is common in patients with heart failure (HF) and is associated with impaired renal function, reduced quality of life, hospital readmissions, and mortality. Current guidelines recommend optimal decongestion using diuretic therapy, mainly loop diuretics. Although acetazolamide has recently demonstrated efficacy in hospitalized patients, its role in ambulatory patients managed through remote telemonitoring remains to be established. This study aims to evaluate the efficacy of oral acetazolamide added to conventional treatment for decongesting ambulatory HF patients during congestive decompensations.
ACHIEVE is a Phase III multicenter, prospective, interventional, randomized, controlled, open-label superiority trial evaluating the efficacy of oral acetazolamide added to conventional treatment for decongestion in ambulatory patients with heart failure during congestive decompensation monitored by remote telemonitoring.
The primary objective is to assess, at Day 5, whether acetazolamide added to conventional treatment improves decongestion compared with standard treatment alone. Secondary objectives include evaluating efficacy, safety, and health economic outcomes, including quality of life, dyspnea, biological markers, unplanned consultations, hospitalizations, mortality, and hospital medical costs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Non-randomization criteria (Criteria should be controlled before patients' randomization) :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ambulatory patients with decompensated heart failure receiving standard treatment with loop diuretics (furosemide) plus oral acetazolamide for up to 5 days. Treatment effectiveness and safety are assessed daily using remote telemonitoring data.
Drug: Acetazolamide · Drug: Furosemide
Ambulatory patients with decompensated heart failure receiving standard treatment with loop diuretics (furosemide) alone for up to 5 days. Treatment effectiveness and safety are assessed daily using remote telemonitoring data.
Drug: Furosemide
Oral acetazolamide initiated at 500 mg (2 tablets) on Day 0. The dose may be adjusted every 48 hours according to the participant's clinical status until Day 5, if necessary.
Standard treatment with loop diuretics (furosemide) administered for up to 5 days according to standard clinical practice.
Percentage of participants with weight loss >2 kg at Day
Percentage of participants who achieve a body weight loss greater than 2 kg between baseline (Day 0) and Day 5, measured using a connected scale through the remote telemonitoring system. Comparison between the experimental and control groups.
Time frame: Day 5
Efficacy : Percentage of weight variation
Percentage change in body weight between Day 0 and Day 5 measured using a connected scale through the remote telemonitoring system.
Time frame: Day 0 to Day 5
Efficacy : Diuretic effectiveness
Diuretic effectiveness assessed by urinary sodium excretion (natriuresis) corrected for loop diuretic exposure, expressed according to furosemide-equivalent dose administered up to Day 5.
Time frame: Day 5
Efficacy : Change in NT-proBNP concentration
Change in plasma NT-proBNP concentration measured from blood samples between baseline and Day 5.
Time frame: Day 0 to Day 5
Efficacy : Change in health-related quality of life (EQ-5D-5L)
Change in EQ-5D-5L score between baseline (Day 0) and Day 5. The EQ-5D-5L is a validated generic quality-of-life questionnaire assessing five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).Each question has 5 levels of answers: No problem, slight problems, moderate problems, severe problems and unable to/ extreme problems. It also includes a visual analogue scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Day 0 to Day 5
Efficacy : Change in dyspnea Visual Analogue Scale (VAS) score
Change in dyspnea severity assessed using a Visual Analogue Scale (VAS) between baseline (Day 0) and Day 5. The VAS ranges from 0 (no shortness of breath) to 10 (worst shortness of breath imaginable).
Time frame: Day 0 to Day 5
Efficacy : Rate of unplanned consultation or hospitalization for heart failure
Percentage of participants requiring an unplanned medical consultation, emergency department visit, or hospitalization for heart failure
Time frame: Day 90
Efficacy : All-cause mortality
Percentage of participants who die from any cause.
Time frame: Day 90
Efficacy : All-cause mortality and Heart failure-related mortality
Percentage of participants who die any cause or from heart failure during follow-up.
Time frame: Day 90
Efficacy : Change in clinical congestion parameters
Evolution of clinical congestion including body weight, dyspnea VAS score, blood pressure, heart rate, and signs of right- and left-sided heart failure collected during follow-up visits.
Time frame: At Day 15
Efficacy : Change in NT-proBNP concentration
Change in plasma NT-proBNP concentration measured on blood samples collected after the acute treatment period.
Time frame: At Day 15
Safety : Change in serum sodium concentration
Assessment of the change in serum sodium concentration between baseline Day 0 and Day 5 to evaluate electrolyte disturbances associated with treatment.
Time frame: Day 0 to Day 5
Safety : Percentage of participants with serum sodium <125 mmol/L
Percentage of participants presenting severe hyponatremia, defined as a serum sodium concentration below 125 mmol/L, on Day 5.
Time frame: Day 5
Safety: Incidence of acute kidney injury (KDIGO stage ≥2)
Percentage of participants developing acute kidney injury defined as Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 or higher between D0 and D5.
Time frame: Day 0 to Day 5
Safety : Change in serum potassium concentration
Assessment of the change in serum potassium concentration between baseline Day 0 and Day 5 to evaluate treatment related electrolyte abnormalities.
Time frame: Day 0 to Day 5
Safety: Percentage of participants with serum potassium <2.5 mmol/L
Percentage of participants presenting severe hypokalemia, defined as a serum potassium concentration below 2.5 mmol/L, on Day 5.
Time frame: Day 5
Safety: Change in serum bicarbonate concentration from Day 0 to Day 5
Assessment of the change in serum bicarbonate concentration between baseline Day 0 and Day 5 to evaluate metabolic changes associated with treatment.
Time frame: Day 0 to Day 5
Percentage of participants with serum bicarbonate <20 mmol/L
Percentage of participants presenting serum bicarbonate concentrations below 20 mmol/L on Day 5.
Time frame: Day 5
Safety: Change in systolic blood pressure
Assessment of the change in systolic blood pressure between baseline Day 0 and Day 5 during treatment.
Time frame: Day 0 to Day 5
Safety: Percentage of participants with systolic blood pressure <90 mmHg
Percentage of participants presenting systolic blood pressure below 90 mmHg during treatment.
Time frame: Day 0 to day 5
Safety: Incidence of low cardiac output or cardiogenic shock
Percentage of participants developing low cardiac output syndrome or cardiogenic shock between D0 and D5.
Time frame: Day 0 to Day 5
Safety: Hospitalization due to treatment failure or poor treatment tolerance
Percentage of participants requiring hospitalization because of treatment failure or poor treatment tolerance.
Time frame: Day 5 and Day 15
Medicoeconomic: Hospital medical costs
Difference in direct hospital medical costs related to unplanned consultations, emergency department visits, or hospitalizations between the experimental and control groups. Costs will be assessed using actual reimbursement tariffs and hospital revenues.
Time frame: Day 90
Start is estimated for Oct 2026; primary completion for Jan 2029, 27 months later.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 27 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetazolamide
University Hospital, Montpellier →